Repression of human telomerase reverse transcriptase using artificial zinc finger transcription factors

Molecular Cancer Research

Volumn 8, Issue 2, 2010, Pages 246-253

  Sohn, Joon Hyung ^a,b   Yeh, Byung Il ^a   Choi, Jong Whan ^a   Yoon, Joonho ^a   Namkung, Jun ^a   Park, Kwang Kyun ^b   Kim, Hyun Won ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; TELOMERASE REVERSE TRANSCRIPTASE; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEK293; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; GENOME; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE TARGETING; GROWTH INHIBITORS; HUMANS; PROMOTER REGIONS, GENETIC; REGULATORY ELEMENTS, TRANSCRIPTIONAL; REPRESSOR PROTEINS; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION FACTORS; TRANSFECTION; ZINC FINGERS;

EID: 77249106118     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0141     Document Type: Article

References (40)

1. Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer 2005;41:971-9.
2. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
3. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997;276:561-7.
4. Masutomi K, Hahn WC. Telomerase and tumorigenesis. Cancer Lett 2003;194:163-72.
5. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999;59:826-30.
6. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-7.
7. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999;232:97-106.
8. Renaud S, Bosman FT, Benhattar J. Implication of the exon region in the regulation of the human telomerase reverse transcriptase gene promoter. Biochem Biophys Res Commun 2003;300:47-54.
9. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000;28:669-77.
10. Misiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000;20:3764-71.
11. Crowe DL, Nguyen DC, Tsang KJ, Kyo S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 2001;29:2789-94.
12. Oh S, Song Y, Yim J, Kim TK. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem 1999;274:37473-8.
13. Fujimoto K, Kyo S, Takakura M, et al. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res 2000;28:2557-62.
14. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 2002;30:839-65.
15. Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol 2006;57:191-214.
16. Papworth M, Kolasinska P, Minczuk M. Designer zinc-finger proteins and their applications. Gene 2006;366:27-38.
17. Greisman HA, Pabo CO. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Science 1997;275: 657-61.
18. Segal DJ, Dreier B, Beerli RR, Barbas CF III. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences. Proc Natl Acad Sci U S A 1999;96:2758-63.
19. Liu Q, Segal DJ, Ghiara JB, Barbas CF III. Design of polydactyl zincfinger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A 1997;94:5525-30.
20. Beerli RR, Dreier B, Barbas CF III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A 2000;97:1495-500.
21. Magnenat L, Blancafort P, Barbas CF III. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J Mol Biol 2004;341:635-49.
22. Lund CV, Popkov M, Magnenat L, Barbas CF III. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Mol Cell Biol 2005;25:9082-91.
23. Eberhardy SR, Goncalves J, Coelho S, et al. Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol 2006;80:2873-83.
24. Sera T. Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliver Rev 2009;61:513-26.
25. Bae KH, Kwon YD, Shin HC, et al. Human zinc fingers as building blocks in the construction of artificial transcription factors. Nat Biotechnol 2003;21:275-80.
26. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
27. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
28. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000;26:447-50.
29. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003;194:209-19.
30. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79.
31. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008;98:677-83.
32. Kim JS, Pabo CO. Getting a handhold on DNA: design of poly-zinc finger proteins with femtomolar dissociation constants. Proc Natl Acad Sci U S A 1998;95:2812-7.
33. Kwon HS, Shin HC, Kim JS. Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels. Nucleic Acids Res 2005;33:e74.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Methods 2001;25:402-8.
35. Beltran A, Parikh S, Liu Y, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 2007;26:2791-8.
36. Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprograming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008;7:1080-90.
37. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52.
38. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003;301:1038-44.
39. Kabouridis PS. Biological applications of protein transduction technology. Trends Biotechnol 2003;21:498-503.
40. Yun CO, Shin HC, Kim TD, et al. Transduction of artificial transcriptional regulatory proteins into human cells. Nucleic Acids Res 2008;36:e103.